Genflow Bioscience

Podcast

A Disruptive Approach to Longevity Therapies

At Ending Age-Related Diseases 2020, Dr. Eric Leire of Genflow Biosciences discussed his company, explaining what Genflow does and how it is funded. The company is intervening directly in the biology of aging, affecting SIRT6, which, like other sirtuins, is a known regulator of aging. The company intends to develop its SIRT6 plasmid as an epigenomic therapy that will affect downstream hallmarks of aging, potentially providing a broad-based solution to multiple age-related diseases.

 

Share it online!

If you enjoyed the article why not share it with your friends! There’s plenty more to read!

Related Articles

Stay up to date with our progress, news and more